'A turn­ing point for the field': 4 years af­ter Seres fail­ure, Finch posts pos­i­tive mi­cro­bio­me da­ta

In 2016, one of the first mi­cro­bio­me biotechs failed a ma­jor tri­al, cra­ter­ing their stock price and cast­ing a years-long pal­lor on the field. Now, for the sec­ond time in as many months, a mi­cro­bio­me com­pa­ny has re­port­ed pos­i­tive, piv­otal da­ta.

In a Phase II tri­al of 206 pa­tients with re­cur­rent C. diff in­fec­tion — a colon-dam­ag­ing bac­te­ria that of­ten comes back and can oc­ca­sion­al­ly be fa­tal — those who were giv­en Finch Ther­a­peu­tics’ mi­cro­bio­me cap­sule plus an­tibi­otics had a 74.5% chance of go­ing 8 weeks with­out a re­peat in­fec­tion. That com­pared to 61.5% for a con­trol arm that re­ceived an­tibi­otics alone.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.